You have to be registered and logged in for purchasing articles.
Abstract |
Development of a High Throughput Single Nucleotide Polymorphism Screening Method for the Cytochrome P450 1A2 Polymorphisms CYP1A2*1C and CYP1A2*1F Are they Useful as Predictive Markers in Mental Disorders? |
Background: The cytochrome P450 1A2 (CYP1A2) gene encodes one of the most important enzymes of the Phase I drug metabolism, which is involved in the metabolism of many lipophilic xenobiotics, such as haloperidol, theophylline, phenacetine, and others. The recently discovered single nucleotide polymorphisms CYP1A2*1C (- 3860G→A) in the 5’ flanking region of the gene and CYP1A2*1F (-163C→A) in intron 1 seem to interfere with the expression rate or catalytic function of the enzyme. Polymorphism carriers may either have a risk of reduced drug degradation and side effects, or may present with an increased induction of enzymatic activity resulting in clinical non-response to the prescribed therapy. We investigated two populations, a mental disease group and a healthy control group, to identify whether these two genetic variants are correlated with the general development of a mental disorder and if they could potentially be used as predictive markers for manifestation of the same.
|